(Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology and aesthetics portfolio.
The deal, at $19.75 per share in cash, is at a 28 percent premium to Obagi's Tuesday closing price.
Obagi's board has unanimously approved the deal, Valeant said in a statement.
(Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp